-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) has a heterogeneous genome landscape , and some karyotype abnormalities have been shown to significantly and differentially affect clinical outcomes
.
Acquiring 1q22 at diagnosis has also become a high-risk cytogenetic feature.
Multiple myeloma (MM) with heterogeneous genome landscape diagnosis
Here, a foreign research team described the clinical characteristics of a group of patients who gained 1q22 gains over time, and compared the risk characteristics and results compared with a matched control group
.
The study included 63 patients with MM who attended the Mayo Clinic from 1st 2004 to December 2019, who did not have a 1q22 increase at the time of diagnosis and were obtained during follow-up, and compared them with 63 patients who did not get a 1q22 increase in similar follow-ups The control group of patients were compared
The research team described the clinical characteristics of a group of patients who gained 1q22 over time, and compared the risk characteristics and outcomes compared to a matched control group
They also compared the results of the acquired 1q22 gain group with the results of 126 patients with 1q22 gain at diagnosis
.
The incidence of acquired 1q22 gain was 6.
The study found that MM patients who received 1q22 gain had worse OS compared with patients who did not get 1q22 gain , possibly in a more severe disease setting at baseline, and provided estimates from the diagnosis of patients who found 1q22 gain OS and PFS
.
Older age and the presence of abnormal HR FISH at baseline are the obtained predictions
MM patients with 1q22 gain have poorer OS compared to patients with no 1q22 gain, and estimated OS and PFS are provided in the diagnosis of patients with 1q22 gain
In summary, the study proved that obtaining 1q22 gain is an important molecular event in MM, which is related to the decrease of OS
.
In determining the high-risk patients of this clonal evolution, risk adaptation methods and/or clinical trials should be considered
Obtaining 1q22 gain is an important molecular event in MM, which is related to the decrease of OS
Original source:
Audil HY,Cook JM,Greipp PT,et al.
Leave a message here
